FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1994313553> ?p ?o ?g. }

• W1994313553 endingPage "758" @default.
• W1994313553 startingPage "754" @default.
• W1994313553 abstract "No AccessJournal of UrologyAdult Urology1 Sep 2015The Effect of Duration of Penile Traction Therapy in Patients Undergoing Intralesional Injection Therapy for Peyronie's Disease Faysal A. Yafi, Michael R. Pinsky, Carrie Stewart, Premsant Sangkum, Erhan Ates, Landon W. Trost, Suresh C. Sikka, and Wayne J.G. Hellstrom Faysal A. YafiFaysal A. Yafi Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana More articles by this author , Michael R. PinskyMichael R. Pinsky Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana More articles by this author , Carrie StewartCarrie Stewart Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana More articles by this author , Premsant SangkumPremsant Sangkum Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana More articles by this author , Erhan AtesErhan Ates Akdeniz University School of Medicine, Antalya, Turkey More articles by this author , Landon W. TrostLandon W. Trost Mayo Clinic, Rochester, Minnesota More articles by this author , Suresh C. SikkaSuresh C. Sikka Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana More articles by this author , and Wayne J.G. HellstromWayne J.G. Hellstrom Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana Financial interest and/or other relationship with Abbvie, Allergan, American Medical Systems, Antares, Apricus, Astellas, Auxilium, Coloplast, Endo, Lilly USA, New England Research Institutes Inc., National Institutes of Health, Pfizer, Promescent, Repros Therapeutics and Theralogix. More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.03.092AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: The concomitant use of penile traction therapy with interferon α-2b has been previously described. We present an update on our clinical experience to assess the benefit and duration of daily traction. Materials and Methods: A retrospective review of patients who underwent interferon α-2b therapy between 2001 and 2012 was performed. Charts were reviewed and data collected regarding various patient demographics, vascular parameters, objective length and curvature measurements, and use of penile traction therapy. Penile traction therapy was further stratified according to duration of daily use. Results: A total of 112 patients underwent a median of 12 interferon α-2b injections (range 6 to 24). Daily use of penile traction therapy was reported by 31% of patients. There were no differences in patient demographics, initial vascular status, pretreatment stretched penile length, erect circumference and curvature between patients who followed a penile traction therapy regimen and those who did not. Overall, the use of penile traction therapy did not effect change in penile circumference (with therapy +3.2 mm [SD 6.5] vs no therapy +2.1 mm [SD 7.4], p=0.45), change in curvature (with therapy −8.1 degrees [SD 16.0] vs no therapy −9.9 degrees [SD 11.8], p=0.49) or change in stretched penile length (with therapy +2.4 mm [SD 0.9] vs no therapy +1.3 mm [SD 0.8], p=0.56). Men who used penile traction therapy 3 or more hours per day gained significantly greater stretched penile length compared to those who did not use penile traction therapy (4.4 mm [SD 0.5] vs 1.3 mm [SD 0.8], p=0.04). Conclusions: Routine penile traction therapy during intralesional injection with interferon α-2b for Peyronie's disease may result in a small but subjectively meaningful improvement in stretched penile length, without affecting curvature, if used for at least 3 hours a day. References 1 : The prevalence of Peyronie’s disease: results of a large survey. BJU Int2001; 88: 727. Google Scholar 2 : Subjective and objective analysis of the prevalence of Peyronie’s disease in a population of men presenting for prostate cancer screening. J Urol2004; 171: 2350. Link, Google Scholar 3 : The prevalence of Peyronie’s disease in diabetic patients with erectile dysfunction. Int J Impot Res2007; 19: 213. Google Scholar 4 : Potent men undergoing radical prostatectomy: a prospective study measuring sexual health outcomes and the impact of erectile dysfunction treatments. Urol Oncol2008; 26: 281. Google Scholar 5 : Use of penile extender device in the treatment of penile curvature as a result of Peyronie’s disease. Results of a phase II prospective study. J Sex Med2009; 6: 558. Google Scholar 6 : A retrospective comparative study of traction therapy vs. no traction following tunica albuginea plication or partial excision and grafting for Peyronie’s disease: measured lengths and patient perceptions. J Sex Med2012; 9: 2396. Google Scholar 7 : Intralesional verapamil injections with and without penile traction and oral therapies for management of Peyronie’s disease. J Urol2008; 179: 408. abstract 1186. Link, Google Scholar 8 : Combination of penile traction, intralesional verapamil, and oral therapies for Peyronie’s disease. J Sex Med2012; 9: 288. Google Scholar 9 : Standardization of vascular assessment of erectile dysfunction: standard operating procedures for duplex ultrasound. J Sex Med2013; 10: 120. Google Scholar 10 : Can an external penis stretcher reduce Peyronie’s penile curvature?. Int J Impot Res2001; 13: S21. Google Scholar 11 : Treatment with penile retraction in evolutive Peyronie’s disease with external penis stretching. Int J Impot Res2002; 14: S74. Google Scholar 12 : Managing penile shortening after Peyronie’s disease surgery. J Urol2007; 177: 252. abstract 750. Link, Google Scholar 13 : Penile traction therapy for treatment of Peyronie’s disease: a single-center pilot study. J Sex Med2008; 5: 1468. Google Scholar 14 : Critical analysis of surgery for Peyronie’s disease. Curr Opin Urol2004; 14: 381. Google Scholar 15 : Traction therapy for men with shortened penis prior to penile prosthesis implantation: a pilot study. J Sex Med2011; 8: 2112. Google Scholar 16 : Outcomes of intralesional interferon-α2B for the treatment of Peyronie disease. J Urol2013; 190: 2194. Link, Google Scholar 17 : Effect of penile extender device in increasing penile size in men with shortened penis: preliminary results. J Sex Med2011; 8: 3188. Google Scholar 18 : Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol2013; 190: 199. Link, Google Scholar © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byZiegelmann M, Savage J, Toussi A, Alom M, Yang D, Kohler T and Trost L (2019) Outcomes of a Novel Penile Traction Device in Men with Peyronie’s Disease: A Randomized, Single-Blind, Controlled TrialJournal of Urology, VOL. 202, NO. 3, (599-610), Online publication date: 1-Sep-2019.Ziegelmann M, Viers B, McAlvany K, Bailey G, Savage J and Trost L (2015) Restoration of Penile Function and Patient Satisfaction with Intralesional Collagenase Clostridium Histolyticum Injection for Peyronie’s DiseaseJournal of Urology, VOL. 195, NO. 4 Part 1, (1051-1056), Online publication date: 1-Apr-2016. Volume 194Issue 3September 2015Page: 754-758 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.Keywordsintralesionaltractionpenile indurationinterferon alfa-2binjectionsMetricsAuthor Information Faysal A. Yafi Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana More articles by this author Michael R. Pinsky Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana More articles by this author Carrie Stewart Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana More articles by this author Premsant Sangkum Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana More articles by this author Erhan Ates Akdeniz University School of Medicine, Antalya, Turkey More articles by this author Landon W. Trost Mayo Clinic, Rochester, Minnesota More articles by this author Suresh C. Sikka Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana More articles by this author Wayne J.G. Hellstrom Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana Financial interest and/or other relationship with Abbvie, Allergan, American Medical Systems, Antares, Apricus, Astellas, Auxilium, Coloplast, Endo, Lilly USA, New England Research Institutes Inc., National Institutes of Health, Pfizer, Promescent, Repros Therapeutics and Theralogix. More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W1994313553 created "2016-06-24" @default.
• W1994313553 creator A5007379680 @default.
• W1994313553 creator A5017192713 @default.
• W1994313553 creator A5046083602 @default.
• W1994313553 creator A5053558278 @default.
• W1994313553 creator A5067180577 @default.
• W1994313553 creator A5079427154 @default.
• W1994313553 creator A5084623797 @default.
• W1994313553 creator A5086248618 @default.
• W1994313553 date "2015-09-01" @default.
• W1994313553 modified "2023-10-14" @default.
• W1994313553 title "The Effect of Duration of Penile Traction Therapy in Patients Undergoing Intralesional Injection Therapy for Peyronie's Disease" @default.
• W1994313553 cites W1628383377 @default.
• W1994313553 cites W1780366818 @default.
• W1994313553 cites W1847662742 @default.
• W1994313553 cites W1967854596 @default.
• W1994313553 cites W1995441800 @default.
• W1994313553 cites W1996691662 @default.
• W1994313553 cites W2009278771 @default.
• W1994313553 cites W2019425946 @default.
• W1994313553 cites W2032500729 @default.
• W1994313553 cites W2035600000 @default.
• W1994313553 cites W2093014101 @default.
• W1994313553 cites W2119487790 @default.
• W1994313553 cites W2143562325 @default.
• W1994313553 cites W2167249734 @default.
• W1994313553 cites W2171098927 @default.
• W1994313553 cites W2794807943 @default.
• W1994313553 doi "https://doi.org/10.1016/j.juro.2015.03.092" @default.
• W1994313553 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25804087" @default.
• W1994313553 hasPublicationYear "2015" @default.
• W1994313553 type Work @default.
• W1994313553 sameAs 1994313553 @default.
• W1994313553 citedByCount "42" @default.
• W1994313553 countsByYear W19943135532016 @default.
• W1994313553 countsByYear W19943135532017 @default.
• W1994313553 countsByYear W19943135532018 @default.
• W1994313553 countsByYear W19943135532019 @default.
• W1994313553 countsByYear W19943135532020 @default.
• W1994313553 countsByYear W19943135532021 @default.
• W1994313553 countsByYear W19943135532022 @default.
• W1994313553 countsByYear W19943135532023 @default.
• W1994313553 crossrefType "journal-article" @default.
• W1994313553 hasAuthorship W1994313553A5007379680 @default.
• W1994313553 hasAuthorship W1994313553A5017192713 @default.
• W1994313553 hasAuthorship W1994313553A5046083602 @default.
• W1994313553 hasAuthorship W1994313553A5053558278 @default.
• W1994313553 hasAuthorship W1994313553A5067180577 @default.
• W1994313553 hasAuthorship W1994313553A5079427154 @default.
• W1994313553 hasAuthorship W1994313553A5084623797 @default.
• W1994313553 hasAuthorship W1994313553A5086248618 @default.
• W1994313553 hasConcept C114793014 @default.
• W1994313553 hasConcept C126894567 @default.
• W1994313553 hasConcept C127313418 @default.
• W1994313553 hasConcept C141071460 @default.
• W1994313553 hasConcept C2779145901 @default.
• W1994313553 hasConcept C2779929075 @default.
• W1994313553 hasConcept C38834483 @default.
• W1994313553 hasConcept C71924100 @default.
• W1994313553 hasConceptScore W1994313553C114793014 @default.
• W1994313553 hasConceptScore W1994313553C126894567 @default.
• W1994313553 hasConceptScore W1994313553C127313418 @default.
• W1994313553 hasConceptScore W1994313553C141071460 @default.
• W1994313553 hasConceptScore W1994313553C2779145901 @default.
• W1994313553 hasConceptScore W1994313553C2779929075 @default.
• W1994313553 hasConceptScore W1994313553C38834483 @default.
• W1994313553 hasConceptScore W1994313553C71924100 @default.
• W1994313553 hasIssue "3" @default.
• W1994313553 hasLocation W19943135531 @default.
• W1994313553 hasLocation W19943135532 @default.
• W1994313553 hasOpenAccess W1994313553 @default.
• W1994313553 hasPrimaryLocation W19943135531 @default.
• W1994313553 hasRelatedWork W1535771998 @default.
• W1994313553 hasRelatedWork W1963931039 @default.
• W1994313553 hasRelatedWork W1967416111 @default.
• W1994313553 hasRelatedWork W2012654321 @default.
• W1994313553 hasRelatedWork W2040952763 @default.
• W1994313553 hasRelatedWork W2097613306 @default.
• W1994313553 hasRelatedWork W2727159746 @default.
• W1994313553 hasRelatedWork W2898295222 @default.
• W1994313553 hasRelatedWork W2923883948 @default.
• W1994313553 hasRelatedWork W2934390355 @default.
• W1994313553 hasVolume "194" @default.
• W1994313553 isParatext "false" @default.
• W1994313553 isRetracted "false" @default.
• W1994313553 magId "1994313553" @default.
• W1994313553 workType "article" @default.